证券代码：300204 证券简称：舒泰神 公告编号：2025-048 经审核，监事会认为董事会编制和审核公司 2025 年半年度报告及半年度报 告摘要的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、 完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或重大遗 漏。 《舒泰神（北京）生物制药股份有限公司 2025 年半年度报告》和《舒泰神 （北京）生物制药股份有限公司 2025 年半年度报告摘要》详见中国证监会指定 的创业板信息披露网站。 表决结果：3 票同意、0 票反对、0 票弃权。 特此公告 舒泰神（北京）生物制药股份有限公司 监事会 舒泰神（北京）生物制药股份有限公司 第六届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"舒泰神"或"公司"） 第六届监事会第八次会议（以下简称"本次会议"）的通知以传真、电子邮件等 相结合的方式于 2025 年 08 月 13 日送达。本次会议于 2025 年 08 月 24 日上午 10:00 在北京经济技术开发区经海二路 ...

【2025 年 08 月】 1 舒泰神(北京)生物制药股份有限公司 2025 年半年度报告全文 舒泰神（北京）生物制药股份有限公司 2025 年半年度报告 2 舒泰神(北京)生物制药股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人周志文、主管会计工作负责人王超及会计机构负责人（会计 主管人员）李世诚声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 创新药物研发的风险：医药行业的产品从研发到上市须经历临床前研究、 临床试验、申报注册、获准生产等过程，具有投入大、环节多、开发周期长、 风险高的特点，容易受到不可预测因素的影响。此外，如果公司研发的新药 适应市场需求有限或不被市场接受，可能导致研发投入回报不匹配、经营成 本上升，对公司的盈利水平和成长也会构成不利影响。为此，公司不断改进 和提升研发水平，谨慎选择研发项目，优化研发布局，集中力量推进临床阶 段重点研发项目的进度，同 ...

Group 1 - The chemical pharmaceutical sector increased by 2.53% on August 25, with Shutaishen leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] - Notable gainers in the chemical pharmaceutical sector included: - Buzoushen (300204) with a closing price of 61.00, up 16.17% and a trading volume of 445,500 shares [1] - Haichen Pharmaceutical (300584) with a closing price of 58.95, up 13.61% and a trading volume of 217,200 shares [1] - Changshan Pharmaceutical (300255) with a closing price of 53.25, up 12.84% and a trading volume of 683,900 shares [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 509 million yuan [2] - The top stocks by net inflow from retail investors included: - Anglikang (002940) with a net inflow of 163 million yuan, representing 22.87% of its trading volume [3] - Haichen Pharmaceutical (300584) with a net inflow of 132 million yuan, representing 10.90% of its trading volume [3] - Lingkang Pharmaceutical (603669) with a net inflow of 64.68 million yuan, representing 37.53% of its trading volume [3]

Market Overview - The Shanghai Composite Index closed at 3858.59 points, above the five-day moving average, with an increase of 0.86% [1] - The total trading volume of A-shares reached 2,101.933 billion yuan [1] Stocks Performance - A total of 653 A-shares have surpassed the five-day moving average today [1] - Notable stocks with significant deviation rates include: - AVIC Taida (中航泰达) with a deviation rate of 15.70% and a daily increase of 22.85% [1] - Lepu Medical (乐普医疗) with a deviation rate of 10.15% and a daily increase of 13.05% [1] - Shutaishen (舒泰神) with a deviation rate of 9.97% and a daily increase of 17.84% [1] Additional Stocks with Deviation Rates - Other stocks with notable performance include: - Youyou Green Energy (优优绿能) with a deviation rate of 8.94% and a daily increase of 11.98% [1] - Changshan Pharmaceutical (常山药业) with a deviation rate of 8.86% and a daily increase of 13.44% [1] - Benlang New Materials (奔朗新材) with a deviation rate of 8.75% and a daily increase of 10.10% [1] Summary of Stocks with Lower Deviation Rates - Stocks with smaller deviation rates that just crossed the five-day moving average include: - Dabo Medical (大博医疗) and Pruis (普蕊斯) [1]

Market Performance - Since April 7, A-shares have experienced a continuous upward trend, with the Shanghai Composite Index rising from 3040 points to over 3800 points, marking a cumulative increase of 25.82% over the period [1] - As of August 22, the Shanghai Composite Index closed at 3825.76 points, reaching a 10-year high with a 1.45% increase; the Shenzhen Component Index rose by 2.07% to 12166.06 points, and the ChiNext Index increased by 3.36% to 2682.55 points [1] - The total market capitalization of A-shares reached 102.81 trillion yuan, reflecting a significant increase from 85.68 trillion yuan at the end of the previous year, adding 17.13 trillion yuan in 2023 [3] Individual Stock Performance - From April 7 to August 22, 742 A-shares saw price increases exceeding 50%, with 197 stocks rising over 100%, and 43 stocks increasing over 200% [2] - Notably, the stock Weiye New Materials on the Sci-Tech Innovation Board achieved a remarkable increase of 1009.78%, becoming the first tenfold stock of the year [2] - Other significant gainers include Shutai Shen and *ST Yushun, with increases of 596.42% and 439.96% respectively [2] Industry Performance - All 31 primary industries in the Shenwan index experienced growth from April 7 to August 22, with 27 industries rising over 10% and 16 industries over 20% [2] - The top three performing industries were Electronics, Comprehensive, and Communications, with increases of 51.62%, 48.42%, and 45.76% respectively [2] Investor Participation - Individual investors hold approximately 33% of the A-share market, indicating a net increase of 5.653 trillion yuan in their market value this year [3] - With around 240 million retail investors, the average net gain per investor this year is approximately 23,500 yuan [3]

Group 1 - The core viewpoint of the article highlights the performance of the E Fund Healthcare Industry Mixed A Fund, which has shown significant returns over various time frames [1] - As of August 24, 2025, the latest net value of the fund is 4.7380 yuan, with a weekly return of -0.94%, a three-month return of 31.94%, and a year-to-date return of 55.55% [1] - The fund was established on January 28, 2011, and as of June 30, 2025, it has a total scale of 3.944 billion yuan [1] Group 2 - The top ten stock holdings of the fund include companies such as Heng Rui Medicine, Rejig Bio, Xin Li Tai, BeiGene-U, Hai Si Ke, and others, with a total holding percentage of 58.14% [1] - The fund manager is Yang Zhenshao, who oversees the investment strategy and portfolio management [1]

Group 1 - Changjiang Electric Power's controlling shareholder plans to increase its stake by 4 billion to 8 billion yuan within the next 12 months through secondary market transactions [1] - Goer Technology's subsidiary intends to acquire 100% equity of Shanghai Aolai, enhancing its core competitiveness in micro-nano optical devices [2] - Huakin Technology is planning to issue H-shares and list on the Hong Kong Stock Exchange to accelerate internationalization and enhance overseas financing capabilities [3] Group 2 - Shuyou Shen has received a Phase I clinical research summary report for STSP-0902 eye drops, indicating good safety and tolerability [4] - Yuanlin Co. announced that it has no business related to graphene despite a significant stock price increase, emphasizing the lack of relevant technology and talent [5] - Newnow's subsidiary has received approval for clinical trials of SYS6036 injection, a humanized monoclonal antibody for tumor immunotherapy [6] Group 3 - Kaige Precision's net profit increased by 144% year-on-year in the first half of the year, with revenue of 454 million yuan [7][8] - Chipone Technology's shareholders plan to transfer 5% of the company's shares through a pricing inquiry due to personal funding needs [9] - Tailin Micro is planning to acquire all or part of the equity of Shanghai Panqi Microelectronics, with stock suspension expected for up to 10 trading days [10] Group 4 - Sihua New Materials stated that the application of liquid cooling technology will not significantly impact its operating performance in the short term [11] - Xin'ao Co. plans to privatize Xin'ao Energy Holdings through its wholly-owned subsidiary and has completed the necessary regulatory filings [12] - Jingwang Electronics intends to invest 5 billion yuan in expanding its Zhuhai Jinwan base to enhance its competitive advantage in high-end products [13] Group 5 - Huilv Ecology's subsidiary signed contracts for the construction of a light module production base with a total investment of 700 million yuan [14] - Zhongjian Technology has authorized management to initiate preparations for issuing H-shares and listing on the Hong Kong Stock Exchange [15] - Huayang Lianzhong's stock will be subject to risk warnings and will be renamed ST Huayang starting August 26 [16] Group 6 - Shengyang Co. plans to establish a joint venture to enter the open-source Hongmeng ecosystem business with a registered capital of 50 million yuan [18] - Jiangsu Guotai intends to use up to 12 billion yuan of idle funds for entrusted wealth management in low-risk financial products [19] - Ping An Bank reported a 3.9% decline in net profit for the first half of the year, with a proposed cash dividend of 2.36 yuan per 10 shares [20] Group 7 - Shenkong Co. reported a 926% increase in net profit for the first half of the year, driven by demand in the semiconductor industry [21] - Zhangjiang Hi-Tech's net profit grew by 38.64% year-on-year, with revenue of 1.704 billion yuan [22] - Silan Micro achieved a net profit of 265 million yuan in the first half of the year, reversing a loss from the previous year [23] Group 8 - Ganfeng Lithium reported a net loss of 531 million yuan in the first half of the year, impacted by price adjustments in the lithium industry [24] - Zhaoyi Innovation's net profit increased by 11.31% year-on-year, with revenue of 4.15 billion yuan [25] - Dongxin Co. reported a net loss of 111 million yuan in the first half of the year, despite a revenue increase [26] Group 9 - Pizaihuang's net profit decreased by 16.22% year-on-year, with total revenue of 5.379 billion yuan [27] - Luoyang Molybdenum's net profit increased by 60% year-on-year, achieving a revenue of 94.773 billion yuan [28] - Tongwei Co. reported a net loss of 4.955 billion yuan in the first half of the year, primarily due to price adjustments in the photovoltaic industry [29] Group 10 - Chunzong Technology reported a net loss of 40 million yuan in the first half of the year, with a significant revenue decline [30] - China CNR's net profit increased by 72.48% year-on-year, with a proposed cash dividend of 1.1 yuan per 10 shares [31] - Shennuo Bio's shareholders plan to reduce their holdings by up to 3.43% [32]

Core Viewpoint - The company Shuyou Shen (300204.SZ) has recently obtained the Phase I clinical study summary report for STSP-0902 eye drops, indicating positive safety and tolerability results in healthy subjects [1] Group 1: Clinical Study Results - STSP-0902 eye drops demonstrated good overall safety and tolerability with most adverse events classified as CTCAE Grade 1 [1] - All drug-related adverse events were mild and self-limiting localized ocular reactions [1] - Pharmacokinetic results showed that the trial drug was detectable in all tear samples up to 6 hours after a single dose [1] Group 2: Future Research Implications - No systemic drug exposure or immunogenicity was observed after both single and multiple doses [1] - The study results support the initiation of further clinical trials in patients with neurotrophic keratitis [1]

Core Viewpoint - The company has received the Phase I clinical study summary report for STSP-0902 eye drops, indicating positive safety and tolerability results in healthy subjects, supporting further trials in patients with neurotrophic keratitis [1] Group 1: Clinical Study Results - The drug STSP-0902 is intended for the treatment of neurotrophic keratitis [1] - The overall safety and tolerability of the drug were found to be good in both single and multiple dosing in healthy subjects, with most adverse events classified as CTCAE Grade 1 [1] - Pharmacokinetic results showed that the drug was detectable in all tear samples up to 6 hours after a single dose [1] Group 2: Future Implications - The results of the study support the initiation of further clinical trials in patients suffering from neurotrophic keratitis [1]

Core Viewpoint - The company has obtained the Phase I clinical study summary report for STSP-902 eye drops, which are intended for the treatment of neurotrophic keratitis, indicating progress in its clinical development [1] Group 1: Clinical Development - The company plans to submit the clinical trial application for STSP-902 in April 2024, with approval expected in July 2024 and the first subject dosing completed by October 2024 [1] - The study results demonstrate that both single and multiple doses of STSP-902 eye drops show good overall safety and tolerability in healthy subjects, with no systemic drug exposure or immunogenicity observed [1] - Pharmacokinetic results indicate that the trial drug can still be detected in tear samples 6 hours after a single dose administration [1] Group 2: Future Implications - The results support the initiation of further clinical trials in patients with neurotrophic keratitis, suggesting potential for future therapeutic applications [1]